T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

CAR-T Cell Toxicity and Safety Profiles

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

Scientists identify metabolic pathway driving lung cancer lymph node metastasis

Metabolic reprogramming plays a critical role in shaping the adaptive capabilities of malignant cells during dissemination.

12 Nov 2026

EU-funded project develops mRNA vaccine targeting liver cancer

The European Innovation Council (EIC) is providing approximately €3.8 million in funding for the international research project ADVANCE, in which Universitätsmedizin Frankfurt is participating. The ADVANCE research team aims to develop an mRNA-based cancer vaccine for the treatment of hepatocellular carcinoma (HCC).

10 Nov 2026

Blocking complement factor B halts pancreatic cancer growth

Researchers have identified a promising new target in the treatment of pancreatic cancer. A new study in The American Journal of Pathology, published by Elsevier, demonstrates that blocking complement factor B (CFB), a pivotal enzyme in the alternative complement pathway, halts cancer growth and alters the tumor microenvironment.

9 Nov 2026

CAR-T cell therapy shows promising early results for stiff person syndrome

A multicenter clinical trial evaluating chimeric antigen receptor-T cell therapy (CAR-T cell therapy) for stiff person syndrome (SPS), a rare autoimmune neurologic disorder, has produced promising early results.

9 Nov 2026

CAR T-cell therapy shows promise for difficult-to-treat lupus

A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a new study from researchers at Hospital for Special Surgery (HSS).

8 Nov 2026

Harvard-led team receives $7 million to develop AI co-scientists for cancer research

A team led by Marinka Zitnik, associate professor of biomedical informatics in the Blavatnik Institute at Harvard Medical School, has received a grant of nearly $7 million from Cancer Grand Challenges to create artificial intelligence (AI) "co-scientists" that help cancer researchers analyze data, generate hypotheses, and suggest new experiments, speeding new knowledge and therapies.

6 Nov 2026

$Refractory lichen planus-like lesions reveal underlying systemic T-cell lymphoma$

Refractory lichen planus-like lesions reveal underlying systemic T-cell lymphoma

A 61-year-old man had a 2-year history of painful mucosal lesions and pruritic violaceous plaques on the trunk and extremities.

6 Nov 2026

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, USA, December 12–15, 2026.

6 Nov 2026

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), in a poster session at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026.

5 Nov 2026

Protein DUSP4 prevents immune cell exhaustion in colorectal cancer

The immune system has powerful cells that can recognize and destroy cancer, but this ability can gradually wane when the cells reside within a tumor.

4 Nov 2026

Hyperactive cancer-promoting proteins help tumor cells evade immune attack

The immune system may recognize a cancer cell and still fail to destroy it. Researchers at Hiroshima University and their international collaborators found that hyperactive YAP and TAZ (YAP/TAZ), two cancer-promoting proteins, were associated with genomic instability that may make cancer cells more recognizable to the immune system, while also increasing PD-L2, which helps the cells suppress T-cell attack.

30 Oct 2026

Targeting ANO6 protein weakens pancreatic cancer and boosts immunity

Fox Chase Cancer Center researchers identified a potential therapeutic target for pancreatic cancer after showing that tumor growth can be slowed and immune suppression can be reduced in preclinical trials by blocking a particular protein, called anoctamin 6 (ANO6).

30 Oct 2026

Researchers find simple way to boost engineered T-cell therapies

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a promising new strategy to make cancer-fighting immune cells stronger and potentially longer-lasting, a discovery that could help improve the effectiveness of immunotherapies that use a patient's own immune cells to attack cancer.

29 Oct 2026

COMPASS pathway helps regulatory T cells prevent intestinal inflammation

Trillions of bacteria live in the human gut without triggering an immune response. Scientists at St. Jude Children's Research Hospital have now discovered a gene-regulatory pathway that helps maintain this delicate balance.

28 Oct 2026

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study, which was presented by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24.

26 Oct 2026

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.

23 Oct 2026

Scientists studied one million immune cells and found clues to future disease risk

Researchers developed a single-cell atlas of one million human neutrophils, identifying distinct immune cell populations and gene-expression patterns across tissues, infections, cancer, and other health conditions. Certain neutrophil signatures were associated with metabolic dysfunction, cancer outcomes, and mortality, while higher routine neutrophil counts, even within the normal range, were linked to an increased risk of chronic disease.

22 Oct 2026

New gene-editing platform gives doctors control over cell therapies

An Australian clinician-led research team has developed a gene-editing platform that could give doctors more control over cell therapies, making them more practical for patients with complex immune conditions.

20 Oct 2026

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology.

16 Oct 2026

Ebola vaccine triggers cross reactive T cells against Bundibugyo ebolavirus

The ongoing Bundibugyo ebolavirus (BDBV) outbreak in the Democratic Republic of the Congo is the second-largest Ebolavirus outbreak globally, with more than 6,000 confirmed cases and a mortality rate of 48 percent.

14 Oct 2026

1
2
3
4
...
2918
Next

T Cell

Overview

CAR-T Cell Toxicity and Safety Profiles

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

Latest T Cell News and Research

Scientists identify metabolic pathway driving lung cancer lymph node metastasis

EU-funded project develops mRNA vaccine targeting liver cancer

Blocking complement factor B halts pancreatic cancer growth

CAR-T cell therapy shows promising early results for stiff person syndrome

CAR T-cell therapy shows promise for difficult-to-treat lupus

Harvard-led team receives $7 million to develop AI co-scientists for cancer research

Refractory lichen planus-like lesions reveal underlying systemic T-cell lymphoma

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Protein DUSP4 prevents immune cell exhaustion in colorectal cancer

Hyperactive cancer-promoting proteins help tumor cells evade immune attack

Targeting ANO6 protein weakens pancreatic cancer and boosts immunity

Researchers find simple way to boost engineered T-cell therapies

COMPASS pathway helps regulatory T cells prevent intestinal inflammation

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

Scientists studied one million immune cells and found clues to future disease risk

New gene-editing platform gives doctors control over cell therapies

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

Ebola vaccine triggers cross reactive T cells against Bundibugyo ebolavirus

Immunology eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

T Cell

Overview

Latest T Cell News and Research

Immunology eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Newsletters you may be interested in